Cystic Fibrosis — CFTR Modulator Therapy & Specialist CF Centre Access

Cystic Fibrosis (CF) is a genetic disease caused by mutations in the CFTR (Cystic Fibrosis Transmembrane conductance Regulator) gene. It is inherited in an autosomal recessive pattern — meaning a person must inherit a mutant CFTR gene from both parents to develop CF. CFTR mutations impair a protein that regulates chloride and water movement across cell surfaces, leading to abnormally thick mucus in the airways, pancreas, intestines, liver, and other organs. In the lungs, this thick mucus traps bacteria and causes chronic infection and inflammation, leading to progressive lung damage. CF also causes pancreatic insufficiency (malabsorption), diabetes, and — in males — infertility.

Trikafta (USA) / Kaftrio (Europe) is a CFTR modulator therapy combining three drugs: elexacaftor and tezacaftor (both CFTR correctors that stabilise the misfolded CFTR protein so it can reach the cell surface) and ivacaftor (a CFTR potentiator that helps the corrected CFTR protein open and function properly). It is approved for CF patients aged 2 years and older (or 6 years in some regions) who have at least one F508del CFTR allele — which covers approximately 90% of CF patients globally. Clinical trials showed it improves lung function (FEV₁) by 10–14 percentage points and reduces pulmonary exacerbations by 63%. It represents the most transformative advance in CF history.

Approximately 10% of CF patients have minimal-function mutations on both alleles (such as W1282X or G542X) that produce no functional CFTR protein and are not responsive to current approved CFTR modulators including Trikafta. This is the most significant unmet need in CF. These patients are priority candidates for clinical trials of: inhaled mRNA replacement therapy (which would deliver functional CFTR mRNA directly to airway cells, bypassing the mutation entirely — mutation-agnostic); next-generation small-molecule modulator combinations targeting Class I mutations; and gene therapy approaches using CRISPR or viral vectors. Referral to a specialist CF centre with active clinical trials access is strongly recommended for these patients.

CF life expectancy has increased dramatically over recent decades. In the 1950s, most children with CF did not survive to school age. By 2010, median predicted survival was approximately 37 years. With the introduction of highly effective CFTR modulator therapy — particularly Trikafta/Kaftrio from 2019 onwards — median predicted survival in high-income countries with optimal care and modulator access now exceeds 50 years, and continues to improve. For patients not covered by current modulators, survival remains limited by lung disease progression, though lung transplantation offers additional life years for eligible patients.

A CF pulmonary exacerbation is an acute deterioration in respiratory symptoms — worsening cough, increased sputum production and purulence, breathlessness, reduced exercise tolerance, fever, and declining FEV₁. Exacerbations are typically triggered by increased bacterial burden in the airways (Pseudomonas, Staphylococcus, Haemophilus). Treatment involves: intensive airway clearance (increased frequency of physiotherapy sessions); inhaled bronchodilators; and most importantly, antibiotics tailored to sputum culture results — typically given intravenously for 14 days for severe exacerbations. Prompt and adequate treatment is critical — inadequately treated exacerbations cause permanent FEV₁ decline from which patients do not fully recover.

CF-related diabetes (CFRD) is a unique form of diabetes that develops in approximately 50% of CF adults (and some adolescents). It is caused by progressive destruction of insulin-producing beta cells in the pancreas from scarring and fibrotic obstruction from CF-related pancreatic disease. CFRD is distinct from both Type 1 and Type 2 diabetes — it primarily presents as post-prandial (after-meal) hyperglycaemia rather than fasting glucose elevation, which is why annual oral glucose tolerance testing (not just fasting glucose) is required for diagnosis from age 10. CFRD significantly worsens lung function if untreated. Treatment is with insulin (not oral agents) and significantly improves both glycaemic control and lung function trajectory.

Yes — CF significantly affects fertility, particularly in males. More than 95% of males with CF are infertile due to bilateral congenital absence of the vas deferens (CBAVD) — the tubes that carry sperm from the testes are absent or blocked from birth as a consequence of CFTR dysfunction. However, the testes produce normal sperm, meaning biological fatherhood is possible through testicular sperm extraction (TESE) and intracytoplasmic sperm injection (ICSI) with IVF. Female CF patients have reduced (not absent) fertility due to thickened cervical mucus. With optimal health and specialist obstetric-CF team co-management, pregnancy is possible and increasingly common in women with CF, particularly those on Trikafta.

Bilateral sequential lung transplantation is offered to CF patients with advanced lung disease when medical treatment can no longer prevent progression to respiratory failure. Transplant referral is typically initiated when FEV₁ falls below 30–40% predicted, when oxygen dependence develops, or when quality of life is severely impaired. After transplant, CF does not recur in the donor lungs (since the transplanted lungs have normal CFTR function), though CF manifestations in other organs (sinuses, pancreas, liver) continue. Median survival after CF lung transplantation is 5–8 years. CFTR modulator therapy (Trikafta) is continued post-transplant for its systemic benefits.

Yes. CancerFax connects CF patients and families with specialist accredited CF centres and respiratory physicians — providing expert CFTR genotype review to confirm ETI modulator eligibility, second opinion coordination on transplant timing, access to clinical trials for patients with minimal-function mutations not covered by approved modulators (including mRNA therapy and next-generation modulator trials), and international coordination for patients seeking access to CFTR modulators or lung transplant programmes not available in their home country. We work with specialist CF centres in India, Germany, South Korea, the UAE, and other countries internationally.